• Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a two-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division within the Office of the Assistant Secretary of Preparedness and Response, valued at $100 million for the delivery of BioThrax® (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS). This contract satisfies BARDA’s notice of intent to sole source BioThrax that was issued on December 8, 2016 and is separate from and in addition to the company’s $911 million BioThrax procurement contract with the Centers for Disease Control and Prevention (CDC). BioThrax pricing under this BARDA procurement contract is the same as BioThrax pricing under the CDC follow-on contract.

  • Falcon Communications is looking for a new marketing communications manager

  • 3M Co. has agreed to acquire Scott Safety from Johnson Controls for $2 billion in a deal that would make 3M the largest personal protection equipment maker in the USA.

  • Battelle’s Live-Agent Test Week is an opportunity for manufacturers and developers of personal protective equipment to submit their materials for live chemical agent permeation testing.

  • FLIR Systems, Inc. announced today that it has received a delivery order for 50 U.S. Army Chemical, Biological, Radiological, and Nuclear Dismounted Reconnaissance Sets, Kits, and Outfits (CBRN DR-SKO) systems. The delivery order is under a five-year indefinite delivery, indefinite quantity (IDIQ) contract from the U.S. Department of Defense, in support of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) DR-SKO Program of Record. The order is valued at $54.2 million, with deliveries extending through the second quarter of 2018.

  • Are you working on research which would be of interest to emergency first responders? If so, we’d like to invite you to submit an abstract for our CBRNe World Convergence 2017 which is taking place in Indianapolis (November 6-8).

  • Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics

  • Follow us on Twitter
  • Subscribe to CBRNe news